Detalhe da pesquisa
1.
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Eur J Cancer
; 203: 114039, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598922
2.
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Cancers (Basel)
; 15(4)2023 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36831376
3.
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
Cancers (Basel)
; 15(14)2023 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37509300